Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

4 of 2 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 1(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05166876Phase 2Terminated

Brequinar Combined With Dipyridamole in Patients With Mild to Moderate COVID-19

Role: lead

NCT03760666Phase 1Terminated

A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Role: lead

NCT04575038Phase 2Completed

CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19

Role: lead

NCT04425252Phase 1Completed

Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19

Role: lead

All 4 trials loaded